Table 5. Univariate and multivariate survival analyses for all patients who received neoadjuvant chemotherapy.
| Factors | Univariate analysis | Multivariate analysis (Cox’s model) | |||
|---|---|---|---|---|---|
| P value | P value | HR | 95% CI | ||
| Age | 0.647 | NS | – | – | |
| FIGO stage | 0.980 | NS | – | – | |
| Pathological grade | 0.018 | 0.032 | 4.091 | 1.132–14.781 | |
| Tumor diameter | 0.814 | NS | – | – | |
| Lymph node metastasis | 0.038 | NS | – | – | |
| Parametrial infiltration | 0.752 | NS | – | – | |
| Margins | 0.616 | NS | – | – | |
| Invasive depth | <0.001 | 0.001 | 7.380 | 2.370–22.981 | |
| Corpus uteri infiltration | 0.328 | NS | – | – | |
| LVSI | 0.016 | NS | – | – | |
| Response to chemotherapy | 0.318 | NS | – | – | |
| Pretreatment CD31-MVD | 0.405 | NS | – | – | |
| Pretreatment CD105-MVD | 0.905 | NS | – | – | |
| Pretreatment CD31-Vv | 0.430 | NS | – | – | |
| Pretreatment CD105- Vv | 0.632 | NS | – | – | |
| Posttreatment CD31-MVD | 0.302 | NS | – | – | |
| Posttreatment CD105-MVD | 0.839 | NS | – | – | |
| Posttreatment CD31-Vv | 0.032 | NS | – | – | |
| Pretreatment CD105- Vv | 0.268 | NS | – | – | |
FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; MVD, Microvessel density; Vv, Volume density; NS, no significant; HR, hazard ratio; CI, confidence interval.